MyFinsight
Home
Blog
About
Maturities of marketable
securities
$89,268K
(-28.75%↓ Y/Y)
Proceeds from exercise of
stock options and...
$4,882K
(471.66%↑ Y/Y)
Net cash used in
investing activities
$10,982K
(133.11%↑ Y/Y)
Net cash provided by
financing activities
$4,572K
(-94.48%↓ Y/Y)
Canceled cashflow
$78,286K
Canceled cashflow
$310K
Increase (decrease) in
cash, cash...
-$61,988K
(-6.96%↓ Y/Y)
Canceled cashflow
$15,554K
Stock-based compensation
expense
$11,309K
(-31.69%↓ Y/Y)
Accrued expenses
$6,939K
(244.38%↑ Y/Y)
Non-cash operating lease
expense
$319K
(-36.96%↓ Y/Y)
Depreciation expense
$33K
(-64.52%↓ Y/Y)
Purchases of marketable
securities
$77,268K
(-51.22%↓ Y/Y)
Capitalized internal-use
software costs
$773K
Purchases of property and
equipment
$245K
(337.50%↑ Y/Y)
Payments of tax
withholdings related to...
$310K
(-74.55%↓ Y/Y)
Net cash used in
operating activities
-$77,542K
(27.99%↑ Y/Y)
Canceled cashflow
$18,600K
Other income, net
$13,184K
Net loss
-$83,720K
(40.38%↑ Y/Y)
Canceled cashflow
$13,184K
Accounts payable
-$7,882K
(-148.34%↓ Y/Y)
Prepaid expenses and
other current assets
$2,860K
(141.35%↑ Y/Y)
Amortization of premiums and
discounts on marketable...
$689K
(-68.91%↓ Y/Y)
Other
-$643K
(-21333.33%↓ Y/Y)
Operating lease
liabilities
-$348K
(43.32%↑ Y/Y)
Personnel-related expenses
$18,943K
(-24.05%↓ Y/Y)
Program-specific
expenses-Relutrigine
$13,979K
(-12.00%↓ Y/Y)
Program-specific
expenses-Ulixacaltamide
$13,299K
(-68.26%↓ Y/Y)
Program-specific
expenses-Vormatrigine
$12,878K
(-59.36%↓ Y/Y)
Other segment
expenses
$12,851K
(-15.06%↓ Y/Y)
Stock-based compensation
expense
$11,309K
(-31.69%↓ Y/Y)
Program-specific
expenses-Elsunersen
$8,141K
(291.77%↑ Y/Y)
Program-specific expenses-Other
Early State Assets
$5,471K
(116.93%↑ Y/Y)
Depreciation expense
$33K
(-64.52%↓ Y/Y)
Back
Back
Cash Flow
Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. (PRAX)
source: myfinsight.com